Laboratory markers in IBD: Useful, magic, or unnecessary toys?

Gut

Volumn 55, Issue 3, 2006, Pages 426-431

  Vermeire, S ^a   Van Assche, G ^a   Rutgeerts, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; ALBUMIN; ALPHA1 GLYCOPROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALPROTECTIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; OROSOMUCOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BIOLOGICAL THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ACUTE-PHASE REACTION; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 33144460914     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.069476     Document Type: Review

References (57)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
2. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33:773-8.
3. Niederau C, Backmerhoff F, Schumacher B, et al. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997;44:90-107.
4. Pepys MB, Druguet M, Klass HJ, et al. Immunological studies in inflammatory bowel disease. In: Porter R, Knight J, eds. Immunology of the gut, Ciba Foundation Symposium. Amsterdam: Elsevier/Excerpta Medica/North Holland, 1977:283-97.
5. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
6. Tillet WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of the pneumococcus. J Exp Med 1930;52:561-71.
7. Kushner I. C-reactive protein and the acute-phase response. Hosp Pract (Off Ed). 1990;25:13, 16, 21-8).
8. Tall AR. C-reactive protein reassessed. N Engl J Med 2004;350:1450-2.
9. Pepys MB. C-reactive protein fifty years on. Lancet 1981;1:653-7.
10. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992;37:313-36.
11. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology 1991;23:118-24.
12. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 2002;19:147-54.
13. Saverymuttu SH, Hodgson HJ, Chadwick VS, et al. Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut 1986;27:809-13.
14. Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-19.
15. Szalai AJ, McCrory MA, Cooper GS, et al. Association between baseline levels of C-reactive protein (CRP} and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002;3:14-19.
16. Russell AI, Cunninghame Graham DS, Shepherd C, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137-47.
17. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
18. Willot S, Vermeire S, Ohresser M, et al. C-reactive protein gene polymorphisms are not associated with biological or clinical response to infliximab in Crohn's disease. Gastroenterology 2005;128(suppl):A311.
19. Thomas RD, Westengard JC, Hay KL, et al. Calibration and validation for erythrocyte sedimentation tests. Role of the International Committee on Standardization in Hematology reference procedure. Arch Pathol Lab Med 1993;117:719-23.
20. Bjerrum OW, Nissen MH, Borregaard N. Neutrophil beta-2 microglobulin: an inflammatory mediator. Scand J Immunol 1990;32:233-42.
21. Jensen KB, Jarnum S, Koudahl G, et al. Serum orosomucoid in ulcerative colitis: its relation to clinical activity, protein loss, and turnover of albumin and IgG. Scand J Gastroenterol 1976;11:177-83.
22. Andre C, Descos L, Landais P, et al. Assessment of appropriate laboratory measurements to supplement the Crohn's disease acitivity index. Gut 1981;22:571-4.
23. Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996;91:927-34.
24. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4.
25. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6.
26. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148:105-9.
27. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5.
28. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14:409-12.
29. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450-5.
30. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology 2003;124:1728-37.
31. Tromm A, Tromm CD, Huppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol 1992;27:774-8.
32. Sachar DB, Smith H, Chan S, et al. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol 1986;8:647-50.
33. Sachar DB, Luppescu NE, Bodian C, et al. Erythrocyte sedimentation as a measure of Crohn's disease activity: opposite trends in ileitis versus colitis. J Clin Gastroenterol 1990;12:643-6.
34. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982;12:351-9.
35. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis 2005;11:707-12.
36. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-80.
37. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
38. Descos L, Andre C, Beorghia S, et al. Serum levels of beta-2-microglobulin-a new marker of activity in Crohn's disease. N Engl J Med 1979;301:440-1.
39. Manicourt DH, Orloff S. Serum levels of beta 2-microglobulin in Crohn's disease. N Engl J Med 1980;302:696.
40. Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol 2001;96:2177-83.
41. Ricci G, D'Ambrosi A, Resca D, et al. Comparison of serum total sialic acid, C-reactive protein, alpha 1-acid glycoprotein and beta 2-microglobulin in patients with non-malignant bowel diseases. Biomed Pharmacother 1995;49:259-62.
42. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
43. Pearson TA, Mensah GA, Alexander RW, Centers for Disease Control and Prevention, American Heart Association, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
44. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
45. Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733-7.
46. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-4.
47. Boirivant M, Leoni M, Tariciotti D, et al. The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study. J Clin Gastroenterol 1988;10:401-5.
48. Consigny Y, Modigliani R, Colombel JF, et al. Biological markers of short term relapse in Crohn's disease (CD). Gastroenterology 2001;20(suppl):A53.
49. Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
50. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
51. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8.
52. D'Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse in inflammatory bowel disease? Gastroenterology 2005;128(suppl):A307.
53. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-24.
54. Rutgeerts P, Colombel J, Enns R, et al. Subanalysis from a phase 3 study on the evaluation of natalizumab in active Crohn's disease. Gut 2003;52(suppl):A239.
55. Sandbom WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004;53:1485-93.
56. Schreiber S, Rutgeerts P, Fedorak RN, et al, CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
57. Feagan B, Rutgeerts P, Schreiber S, et al. Low baseline CRP correlates with high placebo remission rate in Crohn's disease Clinical trials at 12 weeks. Gastroenterology 2005;128(suppl 2):A307.